Senicapoc
Senicapoc is a pharmacological agent that was initially developed for the treatment of sickle cell disease. It is a potent and selective inhibitor of the Gardos channel, also known as the KCNN4 or SK4 channel. The Gardos channel is a calcium-activated potassium channel that plays a crucial role in cellular functions such as volume regulation and the maintenance of the membrane potential.
History[edit | edit source]
Senicapoc was developed by ICOS Corporation, a pharmaceutical company based in the United States. The drug was initially tested in clinical trials for the treatment of sickle cell disease. However, despite showing promise in early-stage trials, it failed to meet the primary endpoint in a Phase III trial, leading to the discontinuation of its development for this indication.
Mechanism of Action[edit | edit source]
Senicapoc works by inhibiting the Gardos channel, which is a calcium-activated potassium channel. By blocking this channel, senicapoc prevents the efflux of potassium ions from the cell. This results in an increase in cell hydration and a decrease in the concentration of hemoglobin S, the abnormal form of hemoglobin that causes sickle cell disease.
Clinical Trials[edit | edit source]
In clinical trials, senicapoc was shown to reduce the frequency of sickle cell crises and hospitalizations. However, it did not meet the primary endpoint in a Phase III trial, which was a reduction in the rate of vaso-occlusive events. Despite this, some secondary endpoints were met, suggesting that the drug may have potential benefits for patients with sickle cell disease.
Current Status[edit | edit source]
Following the failure of the Phase III trial, the development of senicapoc for sickle cell disease was discontinued. However, the drug is currently being investigated for other potential indications, including cystic fibrosis and asthma.
See Also[edit | edit source]
This sickle-cell disease related article is a stub. You can help WikiMD by expanding it.
This Cystic fibrosis related article is a stub. You can help WikiMD by expanding it.
| alt="Asthma inhaler icon" /> | This asthma related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
